Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H1N1 - GlaxoSmithKline

Drug Profile

Influenza A virus vaccine H1N1 - GlaxoSmithKline

Alternative Names: A(H1N1) influenza vaccine - GlaxoSmithKline; Arepanrix H1N1; GSK 2340272A; GSK 2340273A; GSK 2340274A; GSK 234072A; H1N1 pandemic influenza virus vaccine - GlaxoSmithKline; Influenza A H1N1 split virion vaccine - GSK; Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) - GlaxoSmithKline; Pandemrix; Pandemrix H1N1; Swine flu vaccine - GSK; Unadjuvanted influenza A (H1N1) vaccine - GSK

Latest Information Update: 20 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 20 Mar 2015 The vaccine is approved in USA, and is in phase-III development in Latin America and Asia
  • 22 Jul 2011 EMA's Committee for Medicinal Products for Human Use completes its review of Pandemrix and the risk of narcolepsy in subjects aged less than 20 years, and recommends the agent only be used in such subjects when the recommended seasonal trivalent influenza vaccine in unavailable and immunisation is still required
  • 18 Apr 2011 EMA's CHMP recommends changes to Pandemrix™ label to include information on a potential risk of narcolepsy in children and adolescents ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top